Archer Advances Biochip Development Toward Commercial Readiness
Archer Materials Limited (ASX: AXE) has progressed its Biochip program into the next phase, focusing on developing a beta prototype aimed at external validation and pre-clinical testing. Following the successful completion of its earlier prototype and initial collaboration phase, the company is now working on integrating chip design, electronics, and user-ready systems into a more advanced format.
The upcoming prototype is expected to improve usability, stability, and real-world performance testing, helping accelerate the transition from concept to product. Archer continues to utilise silicon for current development due to its manufacturing advantages, while maintaining graphene as a future enhancement platform. The company’s core strength lies in its proprietary sensing technology, which enables flexibility across different chip materials and applications. This adaptability supports scalability and reduces development risks, positioning Archer to advance toward clinical trials and broader commercial opportunities in medical diagnostics and advanced sensing technologies.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Archer Advances Biochip Development Toward Commercial Readiness
Archer Materials Limited (ASX: AXE) has progressed its Biochip program into the next phase, focusing on developing a beta prototype aimed at external validation and pre-clinical testing. Following the successful completion of its earlier prototype and initial collaboration phase, the company is now working on integrating chip design, electronics, and user-ready systems into a more advanced format.
The upcoming prototype is expected to improve usability, stability, and real-world performance testing, helping accelerate the transition from concept to product. Archer continues to utilise silicon for current development due to its manufacturing advantages, while maintaining graphene as a future enhancement platform. The company’s core strength lies in its proprietary sensing technology, which enables flexibility across different chip materials and applications. This adaptability supports scalability and reduces development risks, positioning Archer to advance toward clinical trials and broader commercial opportunities in medical diagnostics and advanced sensing technologies.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au